Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Vedanta Biosciences Announces Collaboration with the NYU
Document related concepts
Immune system wikipedia , lookup
Polyclonal B cell response wikipedia , lookup
Molecular mimicry wikipedia , lookup
Autoimmunity wikipedia , lookup
Sjögren syndrome wikipedia , lookup
Innate immune system wikipedia , lookup
Management of multiple sclerosis wikipedia , lookup
Adoptive cell transfer wikipedia , lookup
Immunosuppressive drug wikipedia , lookup
Cancer immunotherapy wikipedia , lookup
Multiple sclerosis research wikipedia , lookup
Transcript
VedantaBiosciencesAnnouncesCollaborationwiththeNYULangoneMedicalCentertoDevelop Microbiome-DerivedImmunotherapiesforCancer Cambridge,Massachusetts,August11,2016—VedantaBiosciences,pioneeringthedevelopmentofa novelclassoftherapiesdesignedtomodulatepathwaysofinteractionbetweenthehumanmicrobiome andthehostimmunesystem,todayannouncedthatithasenteredintoatranslationalcollaborationwith theNYULangoneMedicalCenterfocusedondevelopingnovelmicrobiome-derivedimmunotherapiesfor cancerpatientsbeingtreatedwithcheckpointinhibitors. Underthetermsoftheagreement,VedantawillcollaboratewithagroupofoncologistsledbyJeffreyS. Weber,M.D.,Ph.D.,deputydirectoroftheLauraandIsaacPerlmutterCancerCenteratNYULangoneand arenownedmelanomaandimmunotherapyexpert,onclinicalstudiestosupporttheidentificationofnew microbiome immunotherapies for cancer. The studies will also explore mechanisms by which the gut microbiomeinfluencestheefficacyofcheckpointinhibitorsincancerpatients.Recentresearchpublished inCellbyVedantaco-founderDr.KenyaHondaatKeioUniversity,hassuggestedthathuman-dwelling bacterial strains can activate immune cells in the gut that could be harnessed for immunotherapies. Vedantahasaworldwide,exclusivelicensetoIPcoveringDr.Honda’sdiscovery.Otherfindingsinthefield indicatethatgutbacteriacanpotentiallymodulatethetherapeuticresponsestocheckpointblockades,as wellasotherclassesofcancertherapeutics. “Dr.Weberisapioneerintranslationalresearch,particularlyinimmunotherapyandthedevelopmentof checkpointinhibitors,”saidDr.BruceRoberts,ChiefScientificOfficerofVedanta.“Welookforwardto workingwithDr.WebertoexpandVedanta’sportfolioofimmuneactivatingmicrobialcocktailsforusein standaloneimmunotherapyandincombinationwithcheckpointinhibitors.” “Checkpoint inhibitors are a major advance in cancer therapy, but many patients do not respond to therapy,andsomepatientswhorespondwilleventuallyrelapse,”saidDr.Weber.“Recentdatasuggest animportantroleforthemicrobiomeintheanti-tumoractivityofimmunotherapy,andourotherstudies ofthemicrobiomewillofferinterestingnewclinicalinsightsintohowandwhythesetreatmentswork. Furtherunderstandingoftheroleofthemicrobiomeinimmunotherapeuticresponsesagainstcancermay alsoleadtonewandimprovedtherapies.” AboutVedanta Vedanta Biosciences is pioneering development of a novel class of therapies designed to modulate pathwaysofinteractionbetweenthehumanmicrobiomeandthehostimmunesystem,withclinicaltrials incertainindicationsexpectedtobegininthefirsthalfof2017.FoundedbyPureTechHealth(PureTech Healthplc,PRTC.L)andagroupofworld-renownedexpertsinimmunologyandmicrobiology,Vedanta Biosciencesisaleaderinthemicrobiomefieldwithcapabilitiestodiscover,developandmanufacture drugs based on live commensal microbes. Leveraging its proprietary technology platform and the expertiseofitsteamofscientificcofounders,VedantaBioscienceshasisolatedavastcollectionofhumanassociatedbacterialstrainsandcharacterizedhowtheimmunesystemrecognizesandrespondstothese microbes.Thisworkhasledtotheidentificationofhumancommensalbacteriathatinducearangeof immuneresponses–includinginductionofregulatoryTcellsandTh17cells,amongothers–aswellas thecharacterizationofnovelmolecularmechanismsofmicrobial-hostcommunication.Theseadvances have been published in leading peer-reviewed journals including Science, Nature (multiple), Cell and Nature Immunology. Vedanta has harnessed these biological insights as well as data from clinical translational collaborations to generate a pipeline of programs in development for infectious disease, autoimmune disease, inflammation and immune-oncology. The clinical potential of therapeutic manipulationofthemicrobiomehasbeenvalidatedbymultiplerandomized,controlledtrialsininfectious diseaseandinflammatoryboweldisease. Vedanta’sscientificco-foundershavepioneeredthefieldsofinnateimmunity,Th17andregulatoryTcell biology,andincludeDr.RuslanMedzhitov(ProfessorofImmunobiologyatYale),Dr.AlexanderRudensky (tri-institutional Professor at the Memorial Sloan-Kettering Institute, the Rockefeller University and Cornell University), Dr. Dan Littman (Professor of Molecular Immunology at NYU), Dr. Brett Finlay (ProfessorattheUniversityofBritishColumbia)andDr.KenyaHonda(Professor,SchoolofMedicine,Keio University). Contact: PureTech AllisonMead Director,CommunicationsandInvestorRelations +16176513156 [email protected]
